{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:10:47Z","timestamp":1767863447778,"version":"3.49.0"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI103055"],"award-info":[{"award-number":["R01 AI103055"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI099243"],"award-info":[{"award-number":["R01 AI099243"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            One potential advantage of live attenuated bacterial vaccines is the ability to stimulate responses to antigens which are only expressed during the course of infection. To determine whether the live attenuated cholera vaccine CVD 103-HgR (Vaxchora) results in antibody responses to the\n            <jats:italic>in vivo<\/jats:italic>\n            -induced toxin-coregulated pilus antigen TcpA, we measured IgA and IgG responses to\n            <jats:named-content content-type=\"genus-species\">Vibrio cholerae<\/jats:named-content>\n            O1 El Tor TcpA in a subset of participants in a recently reported experimental challenge study. Participants were challenged with\n            <jats:named-content content-type=\"genus-species\">V. cholerae<\/jats:named-content>\n            O1 El Tor Inaba N16961 either 10 days or 90 days after receiving the vaccine or a placebo. Neither vaccination nor experimental infection with\n            <jats:named-content content-type=\"genus-species\">V. cholerae<\/jats:named-content>\n            alone resulted in a robust TcpA IgG or IgA response, but each did elicit a strong response to cholera toxin. However, compared to placebo recipients, vaccinees had a marked increase in IgG TcpA antibodies following the 90-day challenge, suggesting that vaccination with CVD 103-HgR resulted in priming for a subsequent response to TcpA. No such difference between vaccine and placebo recipients was observed for volunteers challenged 10 days after vaccination, indicating that this was insufficient time for vaccine-induced priming of the TcpA response. The priming of the response to TcpA and potentially other antigens expressed\n            <jats:italic>in vivo<\/jats:italic>\n            by attenuated\n            <jats:named-content content-type=\"genus-species\">V. cholerae<\/jats:named-content>\n            may have relevance to the maintenance of immunity in areas where cholera is endemic.\n          <\/jats:p>","DOI":"10.1128\/cvi.00470-16","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T13:25:01Z","timestamp":1478784301000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae"],"prefix":"10.1128","volume":"24","author":[{"given":"Leslie M.","family":"Mayo-Smith","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub K.","family":"Simon","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7741-5536","authenticated-orcid":false,"given":"Wilbur H.","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Haney","sequence":"additional","affiliation":[{"name":"PaxVax, Inc., Redwood City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[{"name":"PaxVax, Inc., Redwood City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline E.","family":"Lyon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Unit of Infectious Disease and Vaccine Testing Center, University of Vermont College of Medicine, Burlington, Vermont, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Calderwood","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth D.","family":"Kirkpatrick","sequence":"additional","affiliation":[{"name":"Department of Medicine, Unit of Infectious Disease and Vaccine Testing Center, University of Vermont College of Medicine, Burlington, Vermont, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Cohen","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA"},{"name":"Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron M.","family":"Levine","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Gurwith","sequence":"additional","affiliation":[{"name":"PaxVax, Inc., Redwood City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason B.","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"e0003832","DOI":"10.1371\/journal.pntd.0003832","article-title":"Updated global burden of cholera in endemic countries","volume":"9","author":"Ali M","year":"2015","unstructured":"Ali M NelsonARLopezALSackDA. 2015. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis9:e0003832.","journal-title":"PLoS Negl Trop Dis"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/mr.47.4.510-550.1983"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00378-11"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.168.4.1487"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.9.2833"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00047-10"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2628026100"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60436-X"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15328-7"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/151.2.236"},{"key":"e_1_3_2_12_2","first-page":"777","article-title":"The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients","volume":"38","author":"Mosley WH","year":"1968","unstructured":"Mosley WH AhmadSBenensonASAhmedA. 1968. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ38:777\u2013785.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000221"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00369-09"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00037-12"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(79)90119-6"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90080-O"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.59.7.2508-2512.1991"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.8.4448-4454.2004"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.150"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/308655a0"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1993.tb06355.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90120-1"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00601-13"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw145"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.56.1.142-148.1988"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181783adf"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1994.tb00492.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(03)00170-9"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00438-06"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00470-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00470-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T15:43:05Z","timestamp":1627573385000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00470-16"}},"subtitle":[],"editor":[{"given":"Kathryn M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1128\/CVI.00470-16"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00470-16","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2016-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}